 VANCOUVER, Wash., July 21, 2021 GLOBE NEWSWIRE -- Absci Corporation Absci, the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, today announced the pricing of its initial public offering of 12,500,000 shares of common stock at a public offering price of 16.00 per share. All of the shares of common stock are being offered by Absci. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Absci, are expected to be 200.0 million, excluding any exercise of the underwriters option to purchase additional shares. Abscis common stock is expected to begin trading on the Nasdaq Global Select Market on July 22, 2021, under the ticker symbol ABSI. The offering is expected to close on July 26, 2021, subject to the satisfaction of customary closing conditions. In addition, Absci has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. 